Empower Pharmacy got an FDA warning letter. Here's what it means

What the FDA's September 18 letter actually says

The FDA sent the warning letter to Arta Shaun Noorian, founder and CEO of Empower Clinic Services, doing business as Empower Pharmacy, a 503A and 503B compounder based in Houston. Dated September 18, 2026 and posted publicly on the FDA's warning letter database four days later, it lays out four categories of violations: failing to meet the conditions that let a 503A pharmacy compound drugs that are "essentially a copy" of an FDA-approved product, preparing drugs under insanitary conditions, distributing unapproved new drug products, and misbranding.

The FDA names specific products by strength: tirzepatide/niacinamide at 17 mg/2 mg per mL in a 4 mL vial, tirzepatide/niacinamide at 8 mg/2 mg per mL in a 2.5 mL vial, and semaglutide/cyanocobalamin at 5 mg/0.5 mg per mL in a 1 mL vial. These pair the active GLP-1 drug with a B-vitamin, the same modification strategy that roughly 80% of compounded GLP-1 prescriptions used industry-wide by late 2025 to argue they are not straight copies of Zepbound, Mounjaro, Wegovy, or Ozempic.

Why "inordinate amounts" is the phrase that matters

A 503A pharmacy is legally allowed to compound a drug that resembles an FDA-approved product, but only when a prescriber documents a specific clinical reason a patient cannot use the commercial version, and only for that individual patient. What it cannot do is mass-produce copies under the cover of that exception. The FDA's letter states it plainly: "the volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual."

That is the crux of the case. The FDA is not arguing that a semaglutide-plus-B12 formulation can never be legitimate. It is arguing that Empower's order volumes, drawn from monthly production records the agency reviewed for a stretch in mid-to-late 2025, are far too high to represent one-off, patient-specific decisions. The agency redacted the exact figures as confidential, but says the pattern itself is the evidence.

The insanitary-conditions findings, separately

Alongside the copying allegation, the FDA cites specific sterile-production failures: inadequate smoke studies to verify airflow in the ISO 5 critical processing area, media fills that were not run under conditions challenging enough to catch contamination risk, gaps in aseptic equipment maintenance, and incomplete environmental monitoring. These are the same category of finding, though not identical specifics, as an earlier April 2025 warning letter the FDA issued Empower over insanitary conditions. Two warning letters citing sterile-production gaps in under a year and a half is the part of this story that goes beyond a legal argument about labeling and touches product quality directly.

This isn't Empower's first regulatory fight over GLP-1s

The September letter is the third major action against Empower's compounding business tied to GLP-1 drugs since April 2025. First came that earlier warning letter over insanitary conditions. Then, in July 2025, Eli Lilly sued Empower in the Southern District of Texas, accusing it of manufacturing and selling unapproved, untested copies of tirzepatide at commercial scale and misrepresenting their safety. Empower has continued operating throughout, and has stated publicly that it has already remediated many of the issues the FDA raised this time. For the fuller regulatory backdrop this sits inside, including the separate 503B Bulks List proposal aimed at the entire compounding industry, see our tirzepatide compounding breakdown and the semaglutide side of the same rule.

What this means if you use Empower's compounded GLP-1s right now

Practically, nothing changes today. Empower has not been ordered to stop shipping, and the FDA has not recalled any product. The letter starts a clock: Empower has 15 working days to respond with a plan to fix the cited violations, and the FDA will decide from there whether that response is adequate. Past warning letters in this space have taken months to resolve, with the pharmacy continuing to operate throughout.

What is worth acting on now is the underlying question the letter raises for any patient on a compounded GLP-1: does your prescription have a documented clinical reason beyond cost? If your prescriber never wrote down a specific reason you cannot use Zepbound, Mounjaro, Wegovy, or Ozempic directly, that gap is exactly what the FDA's enforcement theory targets, regardless of which pharmacy fills it. For the mechanics of what a legitimate 503A prescription needs to look like, see how compounding pharmacies are regulated and where compounded tirzepatide is still legally available.

How this fits the bigger 2026 crackdown

This letter lands on top of a slower-moving federal effort to close compounding loopholes for GLP-1 drugs generally. The FDA proposed in April 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, a separate action aimed at large-batch outsourcing facilities rather than individual pharmacies. That proposal is still awaiting a final rule. The Empower letter is a narrower, faster-moving enforcement action against one specific company's practices under the existing 503A rules, and it shows the agency is willing to name a major player publicly rather than wait for the broader rulemaking to finish.

The financial backdrop has shifted too. Branded pricing has come down enough that the cost argument for compounding is weaker than it was during the 2022-2024 shortage years. Wegovy is available for $249 a month on Novo Nordisk's subscription program; Zepbound starts at $299 through LillyDirect. See the current numbers in our semaglutide cost breakdown and our tirzepatide cost breakdown, or compare every current legal option side by side at the best GLP-1 programs.

What to do next

If you are currently filling a compounded semaglutide or tirzepatide prescription through Empower, ask your prescriber two things: whether there is a documented clinical justification in your chart beyond cost, and whether your specific product and lot are affected by the sterile-production findings. If the honest answer to the first question is no, it is worth pricing out the current branded subscription options before renewing. If you have a genuine documented need, that is still a legal path, through Empower or another licensed 503A pharmacy, while the company works through the FDA's 15-day response window.

We will update this page if the FDA takes further action, if Empower's response becomes public, or if a recall is issued.